Phs 398 (rev. 9/04), biographical sketch format page

Principal Investigator/Program Director (Last, First, Middle): BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES.
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) NOTE: The Biographical Sketch may not exceed four pages. Follow the formats and instructions on the
attached sample.
A. Positions and Honors. List in chronological order previous positions, concluding with your present position. List
any honors. Include present membership on any Federal Government public advisory committee. Employment:
5/03-present Research Associate Professor, Department of Neurology, University of Kansas, Kansas City, Kansas
1/00 – 5/03
Research Assistant Professor, Department of Neurology, University of Miami, Miami, Florida 1/98 - 1/00 Assistant Professor, Department of Neurology, University of Kansas, Kansas City, Kansas 11/95 - 1/98 Instructor, Department of Neurology, University of Kansas, Kansas City, Kansas
Other Experience
2007-2008 Movement Disorder Society Web Site Committee 2006-2009 Parkinson Study Group, Credentials Committee 2006-2007 Chair, MDS Journal CME Subcommittee 2005-present WE MOVE, Education Committee 2005-2007 American Academy of Neurology Subcommittee on Education for Non-Neurologists 2003-2007 Board of Directors, Parkinson Foundation of the Heartland 2002-present Steering Committee, PROGENI–Parkinson’s Research: The Organized Genetics Initiative – 2002-present First Vice President, International Essential Tremor Foundation 2002-present Movement Disorder Society, Education Committee 2000-present Secretary/Treasurer, Tremor Research Group B. Selected peer-reviewed publications (in chronological order). Do not include publications submitted or in
(selected from 126 peer-reviewed publications) 1. Parkinson Study Group. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol 2006;63:210-216. Tilley BC, Palesch YY, Kieburtz K, Ravina B, Huang P, Elm JJ, Shannon K, Wooten GF, Tanner CM, Goetz GC on behalf of the NET-PD Investigators. Optimizing the ongoing search for new treatments for Parkinson disease using futility studies. Neurology 2006;66:628-633. 3. The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66:664-671. Lyons KE, Pahwa R. Effects of bilateral subthalamic nucleus stimulation on sleep, daytime sleepiness, and PHS 398/2590 (Rev. 09/04, Reissued 4/2006) Biographical Sketch Format Page
early morning dystonia in patients with Parkinson disease. J Neurosurg 2006;104:502-505. Lyons KE, Wilkinson SB, Simpson RK, Ondo WG, Tarsy D, Norregaard T, Hubble JP, Smith DA, Hauser RA, Jankovic J. Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg 2006;104:506-512. 6. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-995. Lyons KE, Pahwa R. Conversion from sustained release carbidopa/levodopa to carbidopa/ levodopa/entacapone (Stalevo) in Parkinson disease patients. Clin Neuropharmacol 2006; 29:73-76. Liu W, McIntire K, Kim SH, Zhang J, Dascalos S, Lyons KE, Pahwa R. Bilateral subthalamic stimulation improves gait initiation in patients with Parkinson’s disease. Gait Posture 2006;23:492-498. Lyons KE, Greene MS, Pahwa R. Open-label trial regarding the use of acupuncture and yin tui na in Parkinson’s disease outpatients: a pilot study on efficacy, tolerability, and quality of life. J Altern Complement Med 2006;12:395-399. Lyons KE, Pahwa R. Freezing of gait after bilateral subthalamic nucleus stimulation for Parkinson’s disease. Clin Neurol Neurosurg 2006;108:461-464. 11. Louis ED, Vonsattel JPG, Honig LS, Ross GW, Lyons KE, Pahwa R. Neuropathologic findings in essential tremor. Neurology 2006;66:1756-1759. 12. Lyons KE, Pahwa R. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa- induced dyskinesia. Clin Neuropharm 2006;29:148-153. 13. Benabid AL, Deuschl G, Lang AE, Lyons KE, Rezai AR. Introduction: deep brain stimulation for Parkinson’s disease. Mov Disord 2006;21(suppl 14):S168-S170. 14. Lang AE, Houeto JL, Krack P, Kubu C, Lyons KE, Moro E, Ondo W, Pahwa R, Poewe W, Troster AI, Uitti R, Voon V. Deep brain stimulation: preoperative issues. Mov Disord 2006;21(suppl 14):S171-S196. 15. Deuschl G, Herzog J, Kleiner-Fisman G, Kubu C, Lozano AM, Lyons KE, Rodriguez-Oroz MC, Tamma F, Troster AI, Vitek JL, Volkmann J, Voon V. Deep brain stimulation: postoperative issues. Mov Disord 2006;21(suppl 14):S219-S237. 16. Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, Lang AE, Deuschl G. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006;21(suppl 14):S290-S304. 17. Huntington Study Group PHAROS Investigators. At risk for Huntington disease. The PHAROS (Prospective Huntington At Risk Observational Study) Cohort Enrolled. Arch Neurol 2006;63:991-998. 18. Lyons KE, Wilkinson SB, Pahwa R. Stimulation of the motor cortex for disabling essential tremor. Clin Neurol Neurosurg 2006;108:564-567. 19. Ushe M, Mink JW, Tabbal SD, Hong M, Gibson PS, Rich KM, Lyons KE, Pahwa R, Perlmutter JS. Postural tremor suppression is dependent on thalamic stimulation frequency. Mov Disord 2006;21:1290-1292. 20. Foroud T, Pankratz N, Martinez M and the PROGENI/GSPD-European Consortium. Chromosome 5 and Parkinson disease. Eur J Hum Genet 2006;14:1106-1110. 21. Elble RJ, Pullman SL, Matsumoto JY, Raethjen J, Deuschl G, Tintner R and the Tremor Research Group. Tremor amplitude is logarithmically related to 4- and 5-point tremor rating scales. Brain 2006;129:2660-2666. 22. Pankratz N, Pauciulo MW, Elsaesser VE, et al and the Parkinson Study Group – PROGENI Investigators. Mutations in DJ-1 are rare in familial Parkinson disease. Neurosci Lett 2006;408:209-213. 23. Pankratz N, Pauciulo MW, Elsaesser VE, et al. and the Parkinson Study Group – PROGENI Investigators. Mutations in LRRK2 other than G2019S are rare in a North American-based sample of familial Parkinson’s disease. Mov Disord 2006;21:2257-2260. 24. Elble RJ for the Tremor Research Group and Conference Attendees. Report from a U.S. conference on essential tremor. Mov Disord 2006;21:2052-2061. Lyons KE, Pahwa R. Prevalence of bone mineral density screening in Parkinson’s disease clinic outpatients. Mov Disord 2006;21:2265-2266. 26. NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007;68:20-28. 27. Ishihara L, Gibson RA, Warren L, Amouri R, Lyons K, et al. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson’s disease families. Mov Disord 2007;22:55-61. 28. Lyons KE, Davis JT, Pahwa R. Subthalamic nucleus stimulation in Parkinson’s disease patients intolerant to levodopa. Stereotact Funct Neurosurg 2007;85:169-174. 29. Pahwa R, Stacy MA, Factor SA, Lyons KE, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007;68:1108-1115. Lyons KE, Pahwa R on behalf of the SP-650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology 2007;68:1262-1267. PHS 398/2590 (Rev. 09/04, Reissued 4/2006) Biographical Sketch Format Page
C. Research Support. List selected ongoing or completed (during the last three years) research projects (federal
and non-federal support). Begin with the projects that are most relevant to the research proposed in this application. Briefly indicate the overall goals of the projects and your role (e.g. PI, Co-Investigator, Consultant) in the research project. Do not list award amounts or percent effort in projects. KU Center for Neuroprotection in Parkinson’s Disease Study 1: NPDCS (NET-PD FS01-2002) FS1- A Multicenter, Double-Blind, Futility Study of Minocycline and Creatine in subjects with early untreated Parkinson's Disease (PD). Study 2: NPDCS (NET-PD FS02-2003) FS Too - A Multicenter, Double-Blind, Pilot Study of CoQ10 and GPI 1485 in subjects with early untreated Parkinson's Disease (PD) Study 3: NS43128 (NET-PD) A Multicenter, double-blind, parallel group, placebo controlled study of creatine in subjects with treated Parkinson’s disease (PD) LS-1 The goal of these studies is to find a compound with neuroprotective properties for PD. Role: Sub-Investigator, Rater National A Feasibility Study to Implement and Evaluate the Use of Telemedicine Technology To Increase Outreach, Education and Awareness of Parkinson’s Disease in Underserved Communities To determine if educational programs and clinical services (PD evaluations and speech therapy) can successfully be performed via telemedicine for patients in rural areas without access to a specialty center. Role: Principle Investigator ND 71,808 104198 2005-2007 GlaxoSmithKline An open label conversion study of pramipexole to ropinirole controlled release (CR) in patients with Parkinson’s disease The goal of this study is to determine the appropriate conversion factor for patients currently on pramipexole multiple times daily who may be switching to the once a day ropinirole CR when available. Role: Sub-Investigator, Rater (Pahwa PI) PHS 398/2590 (Rev. 09/04, Reissued 4/2006) Biographical Sketch Format Page

Source: http://www.kualzheimer.org/Documents/neurology/lyons.pdf